Drug therapy of the idiopathic inflammatory myopathies: predictors of response to prednisone, azathioprine, and methotrexate and a comparison of their efficacy

The American Journal of Medicine

Volumn 94, Issue 4, 1993, Pages 379-387

  Joffe, Marshall M ^a   Love, Lori A ^a   Leff, Richard L ^a   Fraser, David D ^a   Targoff, Ira N ^c,d   Hicks, Jeanne E ^b   Plotz, Paul H ^a   Miller, Frederick W ^a  

^a NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

^d UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID TRANSFER RNA LIGASE; AUTOANTIBODY; AZATHIOPRINE; METHOTREXATE; NUCLEAR PROTEIN; PREDNISONE; SIGNAL RECOGNITION PARTICLE;

ADULT; ARTICLE; CELL INCLUSION; CONNECTIVE TISSUE DISEASE; CORTICOSTEROID THERAPY; DERMATOMYOSITIS; DRUG EFFICACY; FEMALE; HUMAN; IDIOPATHIC DISEASE; INFLAMMATORY DISEASE; MAJOR CLINICAL STUDY; MALE; MYOPATHY; PHASE 2 CLINICAL TRIAL; POLYMYOSITIS; PRIORITY JOURNAL; PROGNOSIS; SEROLOGY; SEX DIFFERENCE;

ADULT; AUTOANTIBODIES; AZATHIOPRINE; COHORT STUDIES; COMPARATIVE STUDY; FEMALE; HUMAN; INCLUSION BODIES; LOGISTIC MODELS; MALE; METHOTREXATE; MYOSITIS; PREDNISONE; PROGNOSIS; RETROSPECTIVE STUDIES; SEX FACTORS; SUPPORT, U.S. GOV'T, P.H.S.; TIME FACTORS; TREATMENT OUTCOME;

EID: 0027403610     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/0002-9343(93)90148-I     Document Type: Article

References (40)

1. Current concepts in the idiopathic inflammatory myopathies: polymyositis, dermatomyositis, and related disorders
2. Polymyositis and dermatomyositis (parts 1 and 2)
3. Polymyositis and dermatomyositis (parts 1 and 2)
4. Polymyositis and dermatomyositis
5. Azathioprine with prednisone for polymyositis. A controlled, clinical trial
6. Prednisone and azathioprine for polymyositis: long-term followup
7. Computer-assisted analysis of 153 patients with polymyositis and dermatomyositis
8. Clinical features and outcome in inflammatory myopathy [abstract A120]
9. Influence of age at onset on the duration of treatment in idiopathic adult polymyositis and dermatomyositis
10. Dermatopolymyositis and other connective tissue diseases: a review of 105 cases
11. Polymyositis—treatment and prognosis. A study of 107 patients
12. Polymyositis: its presentation, morbidity and mortality
13. Prognostic factors in polymyositis/dermatomyositis. A computer-assisted analysis of ninety-two cases
14. Survival in polymyositis: corticosteroids and risk factors
15. Factors affecting survivorship in polymyositis
16. Adult onset polymyositis/dermatomyositis: an analysis of clinical and laboratory features and survival in 76 patients with a review of the literature
17. Humoral immunity and immunogenetics in the idiopathic inflammatory myopathies
18. Inclusion body myositis
19. Inclusion body myositis
20. Controlled trial of plasma exchange and teukapheresis in polymyositis and dermatomyositis
21. Inflammatory myopathy: a review of etiologic and pathogenetic factors
22. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups
23. Autoantibodies to aminoacyl-transfer RNA synthetases for isoleucine and glycine. Two additional synthetases are antigenic in myositis
24. Measurement of antibody to Jo-1 by ELISA and comparison to enzyme inhibitory activity
25. Antibody to signal recognition particle in polymyositis
26. The association between Mi-2 antibodies and dermatomyositis
27. Ordinal regression models for epidemiologic data
28. Large sample confidence intervals for regression standardized risks, risk ratios, and risk differences
29. Modelling and variable selection in epidemiologic analysis
30. Clinical heterogeneity and treatment response in inclusion body myositis
31. Presentation, treatment, and prognosis of idiopathic inflammatory muscle disease in a rural hospital
32. The response to therapy of inclusion body myositis: stabilization as an attainable goal
33. Distinct seasonal patterns in the onset of adult idiopathic inflammatory myopathy in patients with anti-Jo-1 and antisignal recognition particle autoantibodies
34. Prognosis and treatment of polymyositis with particular reference to steroid resistant patients
35. Methotrexate: its use in the rheumatic diseases
36. Polymyositis and dermatomyositis: combined methotrexate and corticosteroid therapy